Christopher H Van Dyck, MD

Professor of Psychiatry, Neurology, and Neurobiology; Director, Alzheimer's Disease Research Unit

Clinical Interests

  • Alzheimer Disease

Patient Care

Accepts new patients? Yes
Patient Type: Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Dorothy Adler Geriatric Assessment Center

Psychiatry: Alzheimer's Disease Research Unit

Yale Medical Group

Clinical Trials

Conditions Study Title
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication (EVP-6126)
PET Imaging of Metabotropic Glutamate Receptor Subtype 5 in Individuals With and at Risk for Alzheimer's Disease
Amyloid imaging in subjects with and at risk for Alzheimer's disease: A positron emission tomography (PET) study
A Phase 2a Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Therapeutic Effects of Intranasally-Administered Insulin (INI) in Adults with Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD) (Protocol ADC-0460INI): The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
Yale Alzheimer's Disease and Related Disorders Biorepository
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD) (Protocol MK-8931-019)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study (Protocol H8A-MC-LZAZ/ADC-040-A4)
A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's Disease (US202; Protocol Number: T817MAUS202 / ADC-047-TCAD).
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication (Protocol EVP-6124-024)
BAN2401-G000-201: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease
A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer's Disease (Protocol DIAN-TU-001)

Edit this profile

Contact Info

Christopher H Van Dyck, MD
Patient Care Locations
Yale Alzheimer's Disease Research Unit1 Church Street, Ste Suite 600
New Haven, CT 06510
874 Howard Avenue
New Haven, CT 06519
Mailing Address
Yale University School of Medicine
One Church Street

New Haven, CT 06510

Alzheimer's Disease Research Unit

Research Image 2

Frequency of psychosis by ApoE e4 carrier status and dementia severity. Mini Mental State Examination (MMSE) score was used to classify AD patients as mild (MMSE>19, n=103), moderate (MMSE=12-19, n=121), or severe (MMSE<12, n=42). Separate multiple logistic regression analyses were performed for each severity category, with presence of psychosis as dependent variable and the following independent variables (in addition to e4 carrier status): age, sex, educational attainment, and MMSE. *Only at the severe stage was the presence of e4 significantly associated with psychosis (odds ratio [OR]=16.61, 95% CI=2.11-130.51, P=.008). (From Zdanys KF , et al. 2007.)